Home » Agilent's Genome Technology to Accelerate Mesothelioma Fight
Agilent's Genome Technology to Accelerate Mesothelioma Fight
April 15, 2005
Agilent Technologies announced that its Human Genome CGH Microarray technology will be used by researchers at Melbourne, Australia's Peter MacCallum Cancer Centre in a three-year study designed to better understand mesothelioma, a cancer found in the lining of the chest, the abdominal cavity and around the heart, usually caused by exposure to asbestos.
KEYWORDS FDAnews Device Daily Bulletin
Upcoming Events
-
21Oct